The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
| dc.contributor.author | Akyildiz, Arif | |
| dc.contributor.author | Guven, Deniz Can | |
| dc.contributor.author | Ozluk, Ahmet Anil | |
| dc.contributor.author | Ismayilov, Rashad | |
| dc.contributor.author | Mutlu, Emel | |
| dc.contributor.author | Unal, Olcun Umit | |
| dc.contributor.author | Yildiz, Ibrahim | |
| dc.contributor.author | Iriagac, Yakup | |
| dc.contributor.author | Turhal, Serdar | |
| dc.contributor.author | Akbas, Sinem | |
| dc.contributor.author | Bayram, Ertugrul | |
| dc.contributor.author | Telli, Tugba Akin | |
| dc.contributor.author | Turkoz, Fatma Paksoy | |
| dc.contributor.author | Ozcelik, Melike | |
| dc.contributor.author | Erciyestepe, Mert | |
| dc.contributor.author | Selvi, Oguzhan | |
| dc.contributor.author | Gulbagci, Burcu | |
| dc.contributor.author | Erturk, Ismail | |
| dc.contributor.author | Isleyen, Zehra Sucuoglu | |
| dc.contributor.author | Kahraman, Seda | |
| dc.contributor.author | Akdag, Mutianur Ozkorkmaz | |
| dc.contributor.author | Hamitoglu, Buket | |
| dc.contributor.author | Unek, Ilkay Tugba | |
| dc.contributor.author | Unal, Caglar | |
| dc.contributor.author | Hacibekiroglu, Ilhan | |
| dc.contributor.author | Arslan, Cagatay | |
| dc.contributor.author | Azizy, Abdulmunir | |
| dc.contributor.author | Helvaci, Kaan | |
| dc.contributor.author | Demirci, Umut | |
| dc.contributor.author | Dizdar, Omer | |
| dc.contributor.author | Basaran, Mert | |
| dc.contributor.author | Goker, Erdem | |
| dc.contributor.author | Sendur, Mehmet Ali | |
| dc.contributor.author | Yalcin, Suayib | |
| dc.date.accessioned | 2025-10-16T15:14:15Z | |
| dc.date.issued | 2023 | |
| dc.identifier.doi | 10.1097/MD.0000000000035950 | |
| dc.identifier.other | WOS:001103423000055 | |
| dc.identifier.uri | https://openaccess.acibadem.edu.tr/handle/11443/6108 | |
| dc.publisher | LIPPINCOTT WILLIAMS \& WILKINS | |
| dc.source | MEDICINE | |
| dc.subject | atezolizumab | |
| dc.subject | bevacizumab | |
| dc.subject | hepatocellular carcinoma | |
| dc.subject | immunotherapy | |
| dc.title | The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey | |
| dc.type | Article |
